GLP-1 Weight Loss in Northern Virginia | MD-Led | Noor MD

Physician-led GLP-1 weight loss across Northern Virginia — semaglutide and tirzepatide, MD-supervised dosing, real labs and real follow-up.

Or call 703-996-4377

GLP-1 Weight Loss in Northern Virginia — The Class, Not Just the Brand

GLP-1 receptor agonists are the most consequential weight-loss class of the last 50 years, and Northern Virginia is saturated with places willing to prescribe them. Most are telehealth mills — a 5-minute intake, a credit card, a vial in the mail, no labs, no follow-up, no one to call when the nausea won't stop. Noor Esthétique & Wellness Center takes the opposite approach. Furhan Qureshi, MD — board-certified in internal medicine — runs every GLP-1 program in our Sterling clinic, with real labs, real titration, and real follow-up. This page covers the GLP-1 class as a whole: semaglutide (Wegovy, Ozempic, compounded) and tirzepatide (Zepbound, Mounjaro, compounded) — how they work, who actually qualifies medically, what physician-supervised dosing looks like, and what to expect in the first 12 weeks. Drug-specific detail lives on our semaglutide and tirzepatide program pages, and a head-to-head comparison lives on the Semaglutide vs Tirzepatide page — all linked in the Related Pages section below.

How GLP-1 Receptor Agonists Work

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after meals. It tells the pancreas to release insulin, tells the stomach to empty more slowly, and tells the brain you are full. GLP-1 receptor agonists are engineered versions of that hormone — semaglutide is GLP-1 alone, tirzepatide is a dual GLP-1 / GIP agonist that engages a second incretin pathway. Both reduce appetite, slow gastric emptying, and improve insulin sensitivity. Average total-body weight loss in the pivotal trials was approximately 15% for semaglutide (STEP) and approximately 21% for tirzepatide (SURMOUNT-1) at 68–72 weeks, with the heaviest patients losing the most. These are class effects — they are not cosmetic doses dressed up as wellness.

Who Actually Qualifies — Medical Candidacy

BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, NAFLD, PCOS-driven insulin resistance)
No personal or family history of medullary thyroid carcinoma or MEN-2 syndrome (absolute contraindication)
No active pancreatitis, severe gastroparesis, or unexplained GI symptoms requiring workup first
Not pregnant, not actively trying to conceive, and able to use contraception during therapy
Baseline labs reviewed: HbA1c, fasting glucose, lipid panel, CMP, TSH, and (when indicated) lipase — done before the first injection, not after

Physician-Supervised Dosing vs Telehealth Mills

The price-shopping difference between $199/month compounded telehealth and an MD-supervised program is not the molecule — it is what surrounds the prescription. Telehealth mills hand you a vial, a syringe, and an app. They do not draw labs. They do not adjust dose for tolerability. They do not screen for thyroid or pancreatic red flags, and they have no way to course-correct when a patient stalls at week 12. Under physician supervision, dose escalation follows a written titration schedule, slowed or paused when nausea, reflux, or constipation are not tolerable. We re-check labs at 3 months. We coordinate with primary care when blood pressure or diabetes meds need to come down. And when a patient is not responding, we look for the reason — undiagnosed hypothyroidism, undertreated sleep apnea, perimenopausal insulin resistance — instead of just pushing the dose higher.

Why Physician-Led GLP-1 Care Matters

GLP-1 therapy is not a wellness add-on — it is a metabolic intervention with real lab requirements, real contraindications, and real follow-up cadence. That is why every program at Noor runs under direct physician oversight rather than being delegated to a coordinator with a refill button.

Read more about our physician-led approach to care — what board-certified medical oversight means for GLP-1 dosing, labs, and follow-up.

What to Expect in the First 12 Weeks

Weeks 1–4 are the dose-finding phase. Most patients start semaglutide at 0.25 mg/week or tirzepatide at 2.5 mg/week. Appetite blunting often shows up in days; weight loss is usually 1–4 lb in the first month. Nausea is the most common side effect and almost always improves with hydration, smaller meals, and patience. Weeks 4–8 are the first escalation. Dose moves up if tolerated, stays flat if it isn't — there is no prize for getting to the top dose fastest. By week 8 most patients are 5–10 lb down, with measurable improvement in cravings and portion size. Weeks 8–12 are the first checkpoint. We re-weigh, re-measure, repeat labs if indicated, and decide whether to escalate further, hold, or change strategy. Patients who fall under the 5% loss-at-12-weeks threshold get a real conversation about whether to switch molecules, add tirzepatide's GIP pathway, or step back and address an underlying driver.

Northern Virginia City Pages

Closer to home, we publish dedicated semaglutide pages for each of our highest-volume service areas. Use the page that fits your commute:

Semaglutide in Sterling, VA — our home clinic
Semaglutide in Ashburn, VA — Brambleton, Broadlands, One Loudoun
Semaglutide in Reston, VA — Reston Town Center, Wiehle-Reston East Metro
Semaglutide in Herndon, VA — Worldgate, Dulles Tech Corridor
Semaglutide in Leesburg, VA — Historic District, Lansdowne, Brambleton west

Why Choose Noor

Medical authority you can trust.

Physician-Led Care

Every protocol is designed and supervised by board-certified medical leadership — not by aestheticians or unlicensed staff.

Board-Certified Expertise

Our medical director brings a USAF Reserves medical background and years of internal medicine experience to every consultation.

Evidence-Based Protocols

Treatments are guided by current peer-reviewed research and adjusted to your individual labs, symptoms, and goals.

Frequently Asked

Questions patients ask before booking.

Who is a candidate for GLP-1 weight loss?

Generally, adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related condition such as type 2 diabetes, hypertension, sleep apnea, or PCOS-driven insulin resistance. Absolute exclusions include personal or family history of medullary thyroid carcinoma or MEN-2, active pancreatitis, and pregnancy. We confirm candidacy at the medical intake — not on a checkout page.

Semaglutide or tirzepatide — which one is right for me?

Tirzepatide produces greater average weight loss in head-to-head data (SURMOUNT vs STEP), but semaglutide has the longer real-world track record and is the right answer for many patients — especially those who have responded well to it before or who tolerate GLP-1-only therapy better. We pick based on your history, prior response, comorbidities, and insurance coverage. The full comparison lives on our semaglutide vs tirzepatide page.

What side effects are common, and which are red flags?

Common and usually self-limiting: nausea, early satiety, constipation, mild reflux, fatigue in the first few weeks. These respond to hydration, smaller meals, and slower titration. Red flags requiring same-day evaluation: severe abdominal pain radiating to the back (possible pancreatitis), persistent vomiting with dehydration, severe gallbladder-type pain, vision changes, or any new neck mass. Our patients have direct lines to reach us when these come up — not a chatbot.

How fast will I see results?

Appetite changes within days. Weight loss usually shows up in the first 2–4 weeks at 1–4 lb. By 12 weeks, most patients are 5–10% down from baseline. The trial data plateau is around 15% (semaglutide) and 20–21% (tirzepatide) at 60+ weeks. Patients who do not hit a 5% loss by 12 weeks get a strategy change, not a higher dose alone.

Is GLP-1 covered by insurance, or do I need compounded?

Coverage varies wildly. Branded Wegovy and Zepbound are sometimes covered for an obesity indication but frequently denied; Ozempic and Mounjaro are typically only covered for diabetes. Compounded semaglutide and tirzepatide from a licensed 503A pharmacy are a legitimate option for many patients when shortages or affordability are barriers — but quality, sterility, and clinician oversight vary widely between providers. We use vetted compounding pharmacies and supervise the program the same way we would a branded prescription.

Related Services